1.57BMarket Cap
LossP/E TTM
Key Figures
22.745Open
22.745High
375.12KVolume
LossP/E TTM
26.36P/E Dynamic
--Dividend TTM
0.50%Turnover Ratio
22.710Prev. Close
21.800Low
5.77MTurnover
LossP/E Static
6.14P/B
0.00%Div Yield TTM
-22.72%ROA
29.75052wk High
1.08Volume Ratio
-122.69MNet Profit
75.19MShares
-1.3662EPS TTM
1.16Beta
-42.02%ROE
11.02052wk Low
4.16%Amplitude
100.00%Gross Margin
1.57BMarket Cap
-4.07Reward/Risk
2.54%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Zymeworks Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 44 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 39.33.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Zymeworks Inc Highlights
StrengthsRisks
Zymeworks Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Zymeworks Inc Info
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Ticker SymbolZYME
CompanyZymeworks Inc
CEOGalbraith (Kenneth H)
Websitehttps://www.zymeworks.com/
Shareholders
FAQs
What is the current price of Zymeworks Inc (ZYME)?
The current price of Zymeworks Inc (ZYME) is 21.94.
What is the symbol of Zymeworks Inc?
The ticker symbol of Zymeworks Inc is ZYME.
What is the 52-week high of Zymeworks Inc?
The 52-week high of Zymeworks Inc is 29.75.
What is the 52-week low of Zymeworks Inc?
The 52-week low of Zymeworks Inc is 11.02.
What is the market capitalization of Zymeworks Inc?
The market capitalization of Zymeworks Inc is 1.57B.
Is Zymeworks Inc (ZYME) currently rated as Buy, Hold, or Sell?
According to analysts, Zymeworks Inc (ZYME) has an overall rating of Buy, with a price target of 39.33.
What is the Earnings Per Share (EPS TTM) of Zymeworks Inc (ZYME)?
The Earnings Per Share (EPS TTM) of Zymeworks Inc (ZYME) is -1.08.
